ELISABETTA DE MATTEIS

Dr. ELISABETTA DE MATTEIS

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Luana ConteLuana Conte
Luana Conte
EREmanuele Rizzo
Emanuele Rizzo
ECEmanuela Civino
Emanuela Civino
PTPaolo Tarantino
Paolo Tarantino
Giorgio De NunzioGiorgio De Nunzio
Giorgio De Nunzio
EMELISABETTA DE MATTEIS
ELISABETTA DE MATTEIS
The association between genetics and lifestyle factors is crucial when determining breast cancer susceptibility, a leading cause of deaths globally. This research aimed to compare the body mass index, smoking behavior, hormonal influences, and BRCA gene mutations between affected patients and healthy individuals, all with a family history of cancer. All these factors were then utilized as features to train a machine learning (ML) model to predict the risk of breast cancer development. Between 2020 and 2023, a total of 1389 women provided detailed lifestyle and risk factor data during visits to a familial cancer center in Italy. Descriptive and inferential statistics were assessed to explore the differences between the groups. Among the various classifiers used, the ensemble of decision trees was the best performer, with a 10-fold cross-validation scheme for training after normalizing the features. The performance of the model was evaluated using the receiver operating characteristic (ROC) curve and its area under the curve (AUC), alongside the accuracy, sensitivity, specificity, precision, and F1 score. Analysis revealed that individuals in the tumor group exhibited a higher risk profile when compared to their healthy counterparts, particularly in terms of the lifestyle and genetic markers. The ML model demonstrated predictive power, with an AUC of 81%, 88% sensitivity, 57% specificity, 78% accuracy, 80% precision, and an F1 score of 0.84. These metrics significantly outperformed traditional statistical prediction models, including the BOADICEA and BCRAT, which showed an AUC below 0.65. This study demonstrated the efficacy of an ML approach in identifying women at higher risk of breast cancer, leveraging lifestyle and genetic factors, with an improved predictive performance over traditional methods.

1 July 2011 in Tumori Journal
Verified
Journal Article
Closed access
ECElena Collovà
Elena Collovà
FSFederica Sebastiani
Federica Sebastiani
EMELISABETTA DE MATTEIS
ELISABETTA DE MATTEIS
Daniele GeneraliDaniele Generali
Daniele Generali
GAGaetano Aurilio
Gaetano Aurilio
GCGiorgio Cruciani
Giorgio Cruciani
Aims and background: Metronomic chemotherapy refers to the administration of low doses of cytotoxic agents over a prolonged period of time with no or only short drug-free intervals. It is designed to overcome acquired tumor resistance to chemotherapy and reduce neo-angiogenesis despite a lower toxicity than with standard chemotherapy. The role of metronomic chemotherapy remains controversial, and its optimal therapeutic use has not yet been defined. Methods and study design: The present survey was designed as a short questionnaire and was sent to the medical oncologists registered with Medikey, a national database listing all the Italian oncology specialists linked with the Italian Council of Medical Oncology Hospital Consultants (Collegio Italiano Primari Oncologi Medici Ospedalieri, CIPOMO) and the Italian Association of Medical Oncology (Associazione Italiana di Oncologia Medica, AIOM). The questionnaire was completed on a voluntary basis and it was totally anonymous. Results: The questionnaire was sent to 3,289 oncologists, and 191 (5.8%) actively participated in the survey. Seventy-two percent of responders declared that they had administered a regimen of metronomic chemotherapy at least once. Metronomic chemotherapy is commonly used in advanced breast cancer patients, and inmost cases it was prescribed after failure of at least two lines of treatment. Oral agents such as cyclophosphamide, capecitabine, methotrexate and vinorelbine were the most commonly prescribed drugs. Nearly 60% of responders was believed to have significantly less toxicity with metronomic chemotherapy than with standard chemotherapy. Conclusions: The sample of oncologists who participated in the survey is small but it appears to be representative of the Italian medical oncology community. The answers to the questionnaire indicate a significant interest in metronomic chemotherapy, which is apparently widely prescribed. This is the first large national survey on the use of metronomic chemotherapy. Considering the results, larger research on metronomic chemotherapy is strongly warranted.

3 March 2024 in Computation
Verified
Journal Article
Open access
PDF file
Luana ConteLuana Conte
Luana Conte
EREmanuele Rizzo
Emanuele Rizzo
TGTiziana Grassi
Tiziana Grassi
FBFrancesco Bagordo
Francesco Bagordo
EMELISABETTA DE MATTEIS
ELISABETTA DE MATTEIS
Giorgio De NunzioGiorgio De Nunzio
Giorgio De Nunzio
Pedigree charts remain essential in oncological genetic counseling for identifying individuals with an increased risk of developing hereditary tumors. However, this valuable data source often remains confined to paper files, going unused. We propose a computer-aided detection/diagnosis system, based on machine learning and deep learning techniques, capable of the following: (1) assisting genetic oncologists in digitizing paper-based pedigree charts, and in generating new digital ones, and (2) automatically predicting the genetic predisposition risk directly from these digital pedigree charts. To the best of our knowledge, there are no similar studies in the current literature, and consequently, no utilization of software based on artificial intelligence on pedigree charts has been made public yet. By incorporating medical images and other data from omics sciences, there is also a fertile ground for training additional artificial intelligence systems, broadening the software predictive capabilities. We plan to bridge the gap between scientific advancements and practical implementation by modernizing and enhancing existing oncological genetic counseling services. This would mark the pioneering development of an AI-based application designed to enhance various aspects of genetic counseling, leading to improved patient care and advancements in the field of oncogenetics.

21 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MPMARGHERITA PATRUNO
MARGHERITA PATRUNO
SSSimona De Summa
Simona De Summa
NRNicoletta Resta
Nicoletta Resta
MCMariapia Caputo
Mariapia Caputo
SCSilvia Costanzo
Silvia Costanzo
APAngelo Paradiso
Angelo Paradiso
BRCA1/2-associated hereditary breast and ovarian cancer is the most common form of hereditary breast and ovarian cancer and occurs in all ethnicities and racial populations. Different BRCA1/BRCA2 pathogenic variants (PVs) have been reported with a wide variety among populations. In this study, we retrospectively analyzed prevalence and geographic distribution of pathogenic germline BRCA1/2 variants in families from Apulia in southern Italy and evaluated the genotype–phenotype correlations. Data were collected from Oncogenetic Services present in Apulian hospitals and a shared database was built containing Apulian native probands (n = 2026) that had undergone genetic testing from 2004 to 2019. PVs were detected in 499 of 2026 (24.6%) probands and 68.5% of them (342 of 499) were in the BRCA1 gene. We found 65 different PVs in BRCA1 and 46 in BRCA2. There were 10 most recurrent PVs and their geographical distribution appears to be significantly specific for each province. We have assumed that these PVs are related to the historical and geopolitical changes that occurred in Apulia over time and/or to a “founder effect”. Broader knowledge of BRCA1/2 prevalence and recurring PVs in specific geographic areas could help establish more flexible genetic testing strategies that may enhance our ability to detect high-risk subjects.

21 December 2023 in Epidemiologia
Verified
Journal Article
Open access
PDF file
ESEmiliano Sordi
Emiliano Sordi
PPPrisco Piscitelli
Prisco Piscitelli
CACarla Albanese
Carla Albanese
AMAnna Melcarne
Anna Melcarne
ATAnna Tardio
Anna Tardio
ACAdele Civino
Adele Civino
Background and Objectives: Non-melanoma skin cancers (NMSCs) include basal cell carcinoma (BCC) and squamous-cell carcinoma (SCC), as well as a wide range of rare skin tumors. NMSCs is the most frequently diagnosed type of tumor among Caucasians. We aimed at estimating the incidence and mortality of NMSCs in the Salento area (Lecce province, Southern Italy), whose population is assumed to experience heavy and frequent sun exposure due to climatic/environmental factors, both for working and leisure activities. Materials and Methods: We computed the incidence of NMSCs in the Province of Lecce by examining the comprehensive real-world data collected by the local cancer registry, which covers all the 830,000 inhabitants, over a period of fifteen years (from 2003 to 2017), with a focus on the latest 5 years (2013–2017) for the analysis of the different histologic morphologies of these tumors. The incidence of NMSCs has been described in terms of absolute frequencies, crude rates and age-adjusted direct standardized rates (DSR). Joinpoint analysis was used to examine temporal trends in the incidence of NMSCs and estimate annual percent changes (APCs). Results: During the period of 2003–2017, the incidence of NMSCs reached a direct standardized rate (DSR) of 162.62 per 100,000 in men (mortality 1.57 per 100,000) and 89.36 per 100,000 in women (mortality 0.52 per 100,000), respectively. The incidence significantly increased among both men and women across the entire period. Basal cell carcinoma (BCC), with its different morphologies, represented about 67.6% of the NMSCs in men (n = 2139 out of a total of 3161 tumors observed between 2013 and 2017) and about 75.8% of the NMSCs in women (n = 1718 out of a total of 2264 tumors from 2013 to 2017), thus accounting for the vast majority of NMSCs. The results are consistent with the literature data carried out both at national and international level. Conclusions: Proper monitoring of this phenomenon through timely reporting and recording of all new NMSC cases is necessary to develop new preventive strategies.

Verified
Journal Article
Open access
PDF file
MTMaria Rosaria Tumolo
Maria Rosaria Tumolo
Luana ConteLuana Conte
Luana Conte
RGROBERTO GUARINO
ROBERTO GUARINO
UGUgo De Giorgi
Ugo De Giorgi
EMELISABETTA DE MATTEIS
ELISABETTA DE MATTEIS
SSSaverio Sabina
Saverio Sabina
Breast cancer (BC) is the most frequently diagnosed malignancy in women and remains a leading cause of cancer-related mortality worldwide. Among the oncogenic microRNAs, hsa-miR-21 has been consistently implicated in tumorigenesis, yet a comprehensive network-level understanding of its regulatory landscape in BC is lacking. In this study, we performed an integrative bioinformatics analysis to characterize the molecular pathways and prognostic impact of hsa-miR-21. Experimentally validated mRNA targets were retrieved from miRTarBase and used to construct a high-confidence protein–protein interaction network via STRING, followed by hub-gene prioritization in Cytoscape. Functional enrichment analyses were conducted with DAVID to assess Gene Ontology (GO) categories and KEGG pathways. Survival analyses were performed in large BC cohorts from METABRIC and TCGA using the Kaplan–Meier Plotter. We identified 12 hub genes that are central regulators of apoptosis, proliferation, immune signaling, and transcriptional control. GO and KEGG analyses revealed enrichment in cancer-related, immune, and metabolic pathways, underscoring the pleiotropic role of miR-21. While miR-21 expression alone was not significantly associated with overall survival, a composite hub-gene signature demonstrated strong prognostic value. These findings highlight the importance of network-level biomarkers in BC and provide a reproducible framework for dissecting the clinical relevance of disease-associated miRNAs.